Gentolex Chemicals manufactures and distributes high-purity active pharmaceutical ingredients (APIs), custom peptides, and chemical intermediates under stringent cGMP standards. Browse our core offerings below:
LCZ696 (chemically designated as Sacubitril/Valsartan trisodium hemipentahydrate, CAS Registry No. 936623-90-4) represents a landmark paradigm shift in cardiovascular pharmacotherapy. As the first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI), LCZ696 is not a mere physical admixture of two active pharmaceutical ingredients, but a highly defined, crystalline supramolecular complex consisting of Sacubitril anions, Valsartan anions, sodium cations, and water molecules in a precise 1:1:3:2.5 stoichiometric ratio.
For global pharmaceutical developers and brand owners seeking high-purity contract manufacturing and OEM scalability, sourcing LCZ696 from a qualified, cGMP-compliant OEM factory is critical. The dual-mechanism design of LCZ696 concurrently inhibits neutral endopeptidase (neprilysin; EC 3.4.24.11) via the active metabolite of sacubitril (LBQ657) while selectively blocking the angiotensin II type 1 ($AT_1$) receptor via valsartan. This synergism delivers clinical superiority over traditional Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) in reducing cardiovascular mortality and heart failure hospitalizations.
The global market demand for Sacubitril/Valsartan active pharmaceutical ingredients (APIs) has experienced exponential growth. Driven by expanding therapeutic indications—ranging from Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF) to essential hypertension—the generic transition and contract manufacturing (OEM/CDMO) landscape is expanding rapidly.
With the global cardiovascular drug market projected to surpass $65 Billion by 2030, ARNI formulations are capturing significant market share. Patent expirations in major regulatory zones are prompting generic formulation developers to secure reliable, multi-ton scale OEM LCZ696 API supply partners equipped with comprehensive DMF (Drug Master File) technical dossiers.
Navigating the intellectual property terrain of LCZ696 requires deep expertise in polymorph patents, co-crystal salt structures, and synthesis pathways. OEM partners must provide non-infringing crystal Form I structures, validated particle size distribution (PSD) profiles, and robust risk management for secondary nitrosamine formation.
Gentolex Group strategically balances manufacturing infrastructure with localized regulatory and logistical operational nodes. Operating out of established global representatives, including specialized hubs in Mexico and South Africa, Gentolex streamlines international API delivery across North America, Latin America, EMEA, and APAC regions.
The industrial synthesis of commercial-grade LCZ696 API requires multi-step chemical convergence, asymmetric synthesis, and controlled crystallization kinetics to secure uniform crystal habit and polymorphic purity. Below is an overview of the primary industrial synthesis and processing parameters executed within our 250,000 m² cGMP facilities:
| Synthesis Phase | Key Intermediate / Reaction | Critical Process Parameters (CPPs) | Target Quality Metrics (CQAs) |
|---|---|---|---|
| Phase I: Sacubitril Core | Chiral resolution & biphenyl coupling to construct (2R,4S)-5-(biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid. | Enantioselective hydrogenation temperature (±0.5°C), chiral catalyst ligand ratios. | Chiral Purity > 99.8% ee; Heavy metal residues < 5 ppm. |
| Phase II: Valsartan Core | Condensation of N-(triphenylmethyl)tetrazole valine intermediate with biphenyl imidazole precursor followed by deprotection. | Solvent purity control, complete detritylation under mild acidic conditions. | Unreacted intermediate < 0.05%; Residual solvents compliant with ICH Q3C. |
| Phase III: Co-Crystallization | Stoichiometric addition of Sacubitril free acid, Valsartan free acid, and Sodium Hydroxide in an aqueous-organic solvent matrix. | Precipitation temperature ramp rate, seed crystal addition point, moisture control. | Form I Co-Crystal verification via XRPD, DSC melting endotherm at ~138°C. |
| Phase IV: Micronization | Fluidized jet milling under dry nitrogen blanket to achieve targeted Particle Size Distribution (PSD). | Grinding pressure (4.5–6.0 bar), feed rate control to prevent solid-state conversion. | $D_{90} < 20 \mu m$ or customized micronization specifications based on FDF requirements. |
Our OEM production lines deploy continuous inline monitoring using Process Analytical Technology (PAT), including Near-Infrared (NIR) spectroscopy and focused beam reflectance measurement (FBRM), ensuring batch-to-batch reproducibility and zero risk of phase separation during large-scale crystallization.
To maintain absolute market leadership, Gentolex Group continuously advances its chemical engineering capabilities. Our technology roadmap outlines the integration of artificial intelligence in synthesis route optimization, continuous flow chemistry, and sustainable green manufacturing.
Transitioning key hazardous coupling reaction steps from traditional batch reactors to continuous flow micro-reactors. Benefits include precise thermal management, suppression of side-product formation, higher atom economy, and a 40% reduction in Process Mass Intensity (PMI).
Utilizing machine learning models trained on molecular dynamics simulation data to predict crystal nucleating behavior under diverse thermal and solvent environments. This guarantees absolute polymorph stability and prevents unwanted solvate or hydrate phase transformations.
Upgrading our 250,000 m² global facility with advanced solvent recovery distillations, bio-catalytic synthetic steps, and closed-loop water treatment, establishing industry-leading ESG metrics for OEM API production.
Gentolex Chemicals provides end-to-end B2B solutions tailored for multinational pharmaceutical corporations, generic drug manufacturers, and regional distributors. We simplify the complex journey from API synthesis to commercial finished dosage forms (FDF).
Flexible synthesis scales ranging from lab-scale validation batches (gram scale) to commercial multi-ton production lots backed by comprehensive analytical testing protocols (HPLC, LC-MS, NMR, XRPD, TGA).
Complete Finished Dosage Form (FDF) transfer packages including stability data (Zone II, Zone IVb), bioequivalence guidance, and ready-to-file eCTD Module 3 regulatory documentation.
Expert guidance on analytical method development, cleaning validation, isolator setup for high-containment APIs, and regulatory audit readiness for FDA, EMA, and NMPA inspections.
Resilient supply networks supported by international sales offices and logistics nodes in Mexico and South Africa, ensuring uninterrupted delivery, duty mitigation, and localized support.
Gentolex's goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Our main manufacturing base encompasses an overall factory construction area of 250,000 square meters built strictly under international standards to offer flexible, scalable, and cost-effective solutions for clients globally. Gentolex offers an extensive range of APIs and intermediates for development studies and commercial applications with cGMP standards from long-term collaborations. Complete Drug Master Files (DMF), Certificate of Analysis (CoA), and regulatory documentation are fully supported for customers worldwide.
Explore our latest scientific monographs and technical bulletins covering synthetic peptide active ingredients, neurological research compounds, and mitochondrial targeting agents:
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous sequence...
Read Full Monograph
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and life-science applications worldwide with full analytical validation...
Read Full Monograph
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation...
Read Full Monograph
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment...
Read Full Monograph
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and bioenergetics...
Read Full MonographExplore the remaining high-purity peptides, synthetic APIs, and strategic chemical intermediates in our catalog:
